Autopsy report · NCT04340232

Safety and Efficacy of Baricitinib for COVID-19

“Could not make FDA required changes”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2, Phase 3

Sponsor

University of Colorado, Denver

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Baricitinib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK
  “Terms could not be met with the FDA.” (69% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (68% match in meaning)
• MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
  “FDA hold on the project” (67% match in meaning)
• BreathID Multi-center HCV Liver Breath Test Study
  “Due to FDA comments, protocol changed; new trial will be proposed shortly” (66% match in meaning)
• Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
  “FDA request as study could not serve as the confirmatory trial.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.